{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-041006","form_type":"8-K","ticker":null,"cik":"0001603207","company_name":"Notable Labs, Ltd.","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.939533+00:00","generated_at":"2026-05-30T14:34:56.720432+00:00","sec_items":["1.03","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Notable Labs files Chapter 7 bankruptcy; all directors resign, officers terminated","bullets":["Filed voluntary Chapter 7 petitions on Oct 13, 2024, in Delaware Bankruptcy Court for itself and four subsidiaries.","A Chapter 7 trustee will be appointed to liquidate assets and pay claims under the Bankruptcy Code.","All directors (Tuomo Pätsi, Dubin, Feinberg, Galen, Graney, Rice) resigned effective Oct 13 upon filing.","CFO Scott A. McPherson, CSO Joseph Wagner, and interim CEO/restructuring officer Kaile A. Zagger terminated Oct 8.","Company has no board members remaining; operations effectively cease."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-041006","json":"https://secwatch.observer/filing/0001493152-24-041006.json","markdown":"https://secwatch.observer/filing/0001493152-24-041006.md","text":"https://secwatch.observer/filing/0001493152-24-041006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224041006/0001493152-24-041006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224041006/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T14:34:56.720432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51f8bdc76c1b00af5d0b2390cf70d58fbe050f8a","claim":"Notable Labs, Ltd. entered chapter 7 in United States Bankruptcy Court for the District of Delaware (petition 2024-10-13).","evidence_excerpt":"After considering strategic alternatives, Notable Labs, Ltd. (the “ Company ” or “ Notable ”) and its subsidiaries filed a voluntary petition for relief (the “ Petitions ”) under the provisions of chapter 7 of title 11 of the United States Code, 11 U.S.C. §§ 101, et seq. (the “ Bankruptcy Code ”) in the United States Bankruptcy Court for the District of Delaware (the “ Bankruptcy Court ”) on October 13, 2024.","evidence_source":"SEC 8-K Item 1.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224041006/0001493152-24-041006-index.htm","confidence":0.9,"family_label":"Distress & Bankruptcy","details":[{"label":"Proceeding","value":"chapter 7"},{"label":"Court","value":"United States Bankruptcy Court for the District of Delaware"},{"label":"Petition","value":"2024-10-13"}],"fact_type":"distress_event"},{"claim_id":"2276bbab43","claim":"Peter Feinberg resigned as Director at Notable Labs, Ltd..","evidence_excerpt":"Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney and Michael Rice tendered their resignations as members of the Company’s and its subsidiaries’ Boards of Directors, which resignations were effective on October 13, 2024 as of immediately following the filing of the Petitions.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224041006/0001493152-24-041006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"28cc151e28","claim":"Thomas I. H. Dubin resigned as Director at Notable Labs, Ltd..","evidence_excerpt":"Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney and Michael Rice tendered their resignations as members of the Company’s and its subsidiaries’ Boards of Directors, which resignations were effective on October 13, 2024 as of immediately following the filing of the Petitions.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224041006/0001493152-24-041006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6d613621ee","claim":"Tuomo Pätsi resigned as Director at Notable Labs, Ltd..","evidence_excerpt":"Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney and Michael Rice tendered their resignations as members of the Company’s and its subsidiaries’ Boards of Directors, which resignations were effective on October 13, 2024 as of immediately following the filing of the Petitions.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224041006/0001493152-24-041006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8a188c8782","claim":"Michele Galen resigned as Director at Notable Labs, Ltd..","evidence_excerpt":"Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney and Michael Rice tendered their resignations as members of the Company’s and its subsidiaries’ Boards of Directors, which resignations were effective on October 13, 2024 as of immediately following the filing of the Petitions.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224041006/0001493152-24-041006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"aa672ccf21","claim":"Kaile A. Zagger was terminated as Chief Restructuring Officer and Interim Chief Executive Officer at Notable Labs, Ltd..","evidence_excerpt":"The Company also terminated Scott A. McPherson, the Company’s Chief Financial Officer, and Joseph Wagner, the Company’s Chief Scientific Officer, each effective October 8, 2024, and the Company’s Chief Restructuring Officer and Interim Chief Executive Officer, Kaile A. Zagger, was also terminated from such positions and became an advisor to the Company effective as of October 8, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224041006/0001493152-24-041006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Restructuring Officer and Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"bc8147dad6","claim":"Scott A. McPherson was terminated as Chief Financial Officer at Notable Labs, Ltd..","evidence_excerpt":"The Company also terminated Scott A. McPherson, the Company’s Chief Financial Officer, and Joseph Wagner, the Company’s Chief Scientific Officer, each effective October 8, 2024, and the Company’s Chief Restructuring Officer and Interim Chief Executive Officer, Kaile A. Zagger, was also terminated from such positions and became an advisor to the Company effective as of October 8, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224041006/0001493152-24-041006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"cdf222d52e","claim":"Michael Rice resigned as Director at Notable Labs, Ltd..","evidence_excerpt":"Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney and Michael Rice tendered their resignations as members of the Company’s and its subsidiaries’ Boards of Directors, which resignations were effective on October 13, 2024 as of immediately following the filing of the Petitions.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224041006/0001493152-24-041006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"debbf4033f","claim":"Thomas Graney resigned as Director at Notable Labs, Ltd..","evidence_excerpt":"Tuomo Pätsi, Thomas I. H. Dubin, Peter Feinberg, Michele Galen, Thomas Graney and Michael Rice tendered their resignations as members of the Company’s and its subsidiaries’ Boards of Directors, which resignations were effective on October 13, 2024 as of immediately following the filing of the Petitions.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224041006/0001493152-24-041006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f27026455b","claim":"Joseph Wagner was terminated as Chief Scientific Officer at Notable Labs, Ltd..","evidence_excerpt":"The Company also terminated Scott A. McPherson, the Company’s Chief Financial Officer, and Joseph Wagner, the Company’s Chief Scientific Officer, each effective October 8, 2024, and the Company’s Chief Restructuring Officer and Interim Chief Executive Officer, Kaile A. Zagger, was also terminated from such positions and became an advisor to the Company effective as of October 8, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224041006/0001493152-24-041006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}